We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,813.00 | 1,810.00 | 1,811.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.85 | 4B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 2382C
Hikma Pharmaceuticals Plc
11 April 2017
Hikma Pharmaceuticals PLC - Vesting of 2014 EIP
LONDON, 11 April 2017: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 10 April 2017 under the 2014 Executive Incentive Plan ("EIP") which was completed on 11 April 2017. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is GBPnil. As indicated in the table below, certain PDMRs have made disposals.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Hot Features
Premium
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Khalid Nabilsi
--- --------------------- -------------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Financial Officer
--- --------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on 10 April 2017
under the 2014 Executive Incentive
Plan (EIP).
--- --------------------- -------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 14,165
--- --------------------- -------------------------------------
d) Aggregated N/A
information
--- --------------------- -------------------------------------
e) Date of the 10 April 2017
transaction
--- --------------------- -------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Riad Mishlawi
--- --------------------- -------------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status EU Vice President and Global Head
of Injectables
--- --------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on 10 April 2017
under the 2014 Executive Incentive
Plan (EIP).
--- --------------------- -------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 13,811
--- --------------------- -------------------------------------
d) Aggregated N/A
information
--- --------------------- -------------------------------------
e) Date of the 10 April 2017
transaction
--- --------------------- -------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
----------------------------------------------------------------
a) Name Michael Raya
-------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status CEO of West-Ward Pharmaceuticals
-------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
-------------------- ------------------------------------------
b) LEI 549300BNS685UXH4JI75
-------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
-------------------- ------------------------------------------
b) Nature of Shares acquired and disposed from
the transaction vesting of the conditional awards
on 10 April 2017 under the 2014 Executive
Incentive Plan (EIP). 7,902 shares
were sold to cover tax and associated
costs and 11,753 shares were retained.
-------------------- ------------------------------------------
c) Price(s) and Price Volume(s)
volume(s) ---------- ----------
GBP19.42 7,902
---------- ----------
GBP0.00 11,753
---------- ----------
-------------------- ------------------------------------------
d) Aggregated GBP20.00
information GBP158,040
-------------------- ------------------------------------------
e) Date of the 10 April 2017
transaction
-------------------- ------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
-------------------- ------------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--------------------------------------------------------------
a) Name Bassam Kanaan
-------------------- ----------------------------------------
2 Reason for the notification
--------------------------------------------------------------
a) Position/status Chief Strategy and Corporate Development
Officer
-------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
-------------------- ----------------------------------------
b) LEI 549300BNS685UXH4JI75
-------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
-------------------- ----------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on 10 April 2017
under the 2014 Executive Incentive
Plan (EIP).
-------------------- ----------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 19,945
-------------------- ----------------------------------------
d) Aggregated N/A
information
-------------------- ----------------------------------------
e) Date of the 10 April 2017
transaction
-------------------- ----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
-------------------- ----------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
----------------------------------------------------------
a) Name Majda Labadi
-------------------- ------------------------------------
2 Reason for the notification
----------------------------------------------------------
a) Position/status Corporate Vice President for Human
Resources and Head of Operations,
MENA
-------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
----------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
-------------------- ------------------------------------
b) LEI 549300BNS685UXH4JI75
-------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
----------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
-------------------- ------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on 10 April 2017
under the 2014 Executive Incentive
Plan (EIP).
-------------------- ------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 10,089
-------------------- ------------------------------------
d) Aggregated N/A
information
-------------------- ------------------------------------
e) Date of the 10 April 2017
transaction
-------------------- ------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
-------------------- ------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBUGDSGGBBGRB
(END) Dow Jones Newswires
April 11, 2017 11:01 ET (15:01 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
